Skeletal Muscle Phenotypically Converts and Selectively Inhibits Metastatic Cells in Mice

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Parlakian, Ara ^a   Gomaa, Iman ^a,d   Solly, Sounkary ^a   Arandel, Ludovic ^a   Mahale, Alka ^c   Born, Gustav ^b   Marazzi, Giovanna ^a   Sassoon, David ^a  

^a INSERM   (France)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d German University in Cairo   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

DESMIN; GREEN FLUORESCENT PROTEIN; MELANIN;

ANIMAL; APOPTOSIS; ARTICLE; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; CELL LINEAGE; COCULTURE; CONFOCAL MICROSCOPY; CULTURE MEDIUM; CYTOLOGY; CYTOTOXICITY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; METASTASIS; MOUSE; MYOBLAST; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; CELL LINEAGE; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; CYTOTOXICITY, IMMUNOLOGIC; DESMIN; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANINS; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MUSCLE, SKELETAL; MYOBLASTS; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77957318337     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009299     Document Type: Article

References (102)

1. Fidler IJ, (1999) Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmacol 43 (Suppl): S3-10.
2. Greig RG, Trainer DL, (1986) Shaping future strategies for the pharmacological control of tumor cell metastases. Cancer Metastasis Rev 5: 3-14.
3. Klein CA, (2008) The direct molecular analysis of metastatic precursor cells in breast cancer: A chance for a better understanding of metastasis and for personalised medicine. Eur J Cancer.
4. Langley RR, Fidler IJ, (2007) Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 28: 297-321.
5. Crissman JD, (1986) Tumor-host interactions as prognostic factors in the histologic assessment of carcinomas. Pathol Annu 21 Pt 1: 29-52.
6. Kopfstein L, Christofori G, (2006) Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci 63: 449-468.
7. Pollard JW, (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78.
8. Fidler IJ, (2002) The organ microenvironment and cancer metastasis. Differentiation 70: 498-505.
9. Fidler IJ, (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458.
10. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, et al.(2005) The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet 37: 1047-1054.
11. Herring CL Jr, Harrelson JM, Scully SP, (1998) Metastatic carcinoma to skeletal muscle. A report of 15 patients. Clin Orthop Relat Res pp. 272-281.
12. Plaza JA, Perez-Montiel D, Mayerson J, Morrison C, Suster S, (2008) Metastases to soft tissue: a review of 118 cases over a 30-year period. Cancer 112: 193-203.
13. Razak AR, Chhabra R, Hughes A, England S, Dildey P, et al.(2007) Muscular metastasis, a rare presentation of non-small-cell lung cancer. MedGenMed 9: 20.
14. Sudo A, Ogihara Y, Shiokawa Y, Fujinami S, Sekiguchi S, (1993) Intramuscular metastasis of carcinoma. Clin Orthop Relat Res pp. 213-217.
15. Armulik A, Abramsson A, Betsholtz C, (2005) Endothelial/pericyte interactions. Circ Res 97: 512-523.
16. Willis R, (1973) The spread of tumors in the body; In: RA W, editors. 279London Butterworths.
17. Paget S, (1889) The distribution of secondary growths in cancer of the breast. Lancet 133: 571-573.
18. Weiss L, Schmid-Schonbein GW, (1989) Biomechanical interactions of cancer cells with the microvasculature during metastasis. Cell Biophys 14: 187-215.
19. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, et al.(1995) Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 122: 327-334.
20. Thune I, Brenn T, Lund E, Gaard M, (1997) Physical activity and the risk of breast cancer. N Engl J Med 336: 1269-1275.
21. Fidler IJ, Hart IR, (1982) Cancer, principles and practice of oncology; De Vita VT hS, Rosenberg SA, editor. Philadelphia: JB Lippincott. Principles of cancer biology, biology of cancer metastasis p.
22. Folkman J, (2006) Angiogenesis. Annu Rev Med 57: 1-18.
23. Constant JS, Feng JJ, Zabel DD, Yuan H, Suh DY, et al.(2000) Lactate elicits vascular endothelial growth factor from macrophages: a possible alternative to hypoxia. Wound Repair Regen 8: 353-360.
24. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, et al.(2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109: 3812-3819.
25. Seely S, (1980) Possible reasons for the high resistance of muscle to cancer. Med Hypotheses 6: 133-137.
26. Pouyssegur J, Franchi A, Pages G, (2001) pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. Novartis Found Symp 240: 186-196; discussion 196-188.
27. Djaldetti M, Sredni B, Zigelman R, Verber M, Fishman P, (1996) Muscle cells produce a low molecular weight factor with anti-cancer activity. Clin Exp Metastasis 14: 189-196.
28. Luo C, Jiang Y, Liu Y, Li X, (2002) Experimental study on mechanism and rarity of metastases in skeletal muscle. Chin Med J (Engl) 115: 1645-1649.
29. Bar-Yehuda S, Barer F, Volfsson L, Fishman P, (2001) Resistance of muscle to tumor metastases: a role for a3 adenosine receptor agonists. Neoplasia 3: 125-131.
30. Fishman P, Bar-Yehuda S, Vagman L, (1998) Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. Cancer Res 58: 3181-3187.
31. Fidler IJ, Nicolson GL, (1976) Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst 57: 1199-1202.
32. Poste G, Doll J, Hart IR, Fidler IJ, (1980) In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 40: 1636-1644.
33. Bertram JS, Janik P, (1980) Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. Cancer Lett 11: 63-73.
34. Miller AJ, Mihm MC Jr, (2006) Melanoma. N Engl J Med 355: 51-65.
35. Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, et al.(2001) Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 117: 294-300.
36. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, et al.(2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41: 544-552.
37. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, et al.(2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15: 294-303.
38. Ibrahim N, Haluska FG, (2009) Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 4: 551-579.
39. Inoue-Narita T, Hamada K, Sasaki T, Hatakeyama S, Fujita S, et al.(2008) Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis. Cancer Res 68: 5760-5768.
40. Larue L, Delmas V, (2006) The WNT/Beta-catenin pathway in melanoma. Front Biosci 11: 733-742.
41. McGary EC, Lev DC, Bar-Eli M, (2002) Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 1: 459-465.
42. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al.(2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122.
43. King R, Weilbaecher KN, McGill G, Cooley E, Mihm M, et al.(1999) Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis. Am J Pathol 155: 731-738.
44. O'Reilly FM, Brat DJ, McAlpine BE, Grossniklaus HE, Folpe AL, et al.(2001) Microphthalmia transcription factor immunohistochemistry: a useful diagnostic marker in the diagnosis and detection of cutaneous melanoma, sentinel lymph node metastases, and extracutaneous melanocytic neoplasms. J Am Acad Dermatol 45: 414-419.
45. Salti GI, Manougian T, Farolan M, Shilkaitis A, Majumdar D, et al.(2000) Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 60: 5012-5016.
46. Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K, et al.(2002) Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model. Life Sci 70: 791-798.
47. Zhu DZ, Cheng CF, Pauli BU, (1991) Mediation of lung metastasis of murine melanomas by a lung-specific endothelial cell adhesion molecule. Proc Natl Acad Sci U S A 88: 9568-9572.
48. Brooks SV, (2003) Current topics for teaching skeletal muscle physiology. Adv Physiol Educ 27: 171-182.
49. Ehrhardt J, Morgan J, (2005) Regenerative capacity of skeletal muscle. Curr Opin Neurol 18: 548-553.
50. Fisher DE, (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542.
51. Olie RA, Zangemeister-Wittke U, (2001) Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential. Drug Resist Updat 4: 9-15.
52. Bellei B, Flori E, Izzo E, Maresca V, Picardo M, (2008) GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes. Cell Signal 20: 1750-1761.
53. Tatzel J, Poser I, Schroeder J, Bosserhoff AK, (2005) Inhibition of melanoma inhibitory activity (MIA) expression in melanoma cells leads to molecular and phenotypic changes. Pigment Cell Res 18: 92-101.
54. Zhang W, Tsan R, Nam DH, Lu W, Fidler IJ, (2006) Loss of adhesion in the circulation converts amelanotic metastatic melanoma cells to melanotic by inhibition of AKT. Neoplasia 8: 543-550.
55. Ewing J, (1928) Metastasis, Neoplastic Disease: A Treatise on tumors. London Philadelphia and London.
56. Netland PA, Zetter BR, (1984) Organ-specific adhesion of metastatic tumor cells in vitro. Science 224: 1113-1115.
57. Netland PA, Zetter BR, (1985) Metastatic potential of B16 melanoma cells after in vitro selection for organ-specific adherence. J Cell Biol 101: 720-724.
58. Obata H, Kuratsu S, Uchida A, Araki N, Myoui A, et al.(2002) Analysis of organ selectivity in the metastatic behavior of Dunn osteosarcoma. Clin Orthop Relat Res pp. 212-222.
59. Sampaolesi M, Blot S, D'Antona G, Granger N, Tonlorenzi R, et al.(2006) Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444: 574-579.
60. Sampaolesi M, Torrente Y, Innocenzi A, Tonlorenzi R, D'Antona G, et al.(2003) Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 301: 487-492.
61. Bystryn JC, Rigel D, Friedman RJ, Kopf A, (1987) Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 123: 1053-1055.
62. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, et al.(1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 9: 689-696.
63. Poser I, Tatzel J, Kuphal S, Bosserhoff AK, (2004) Functional role of MIA in melanocytes and early development of melanoma. Oncogene 23: 6115-6124.
64. Zhao W, Liu H, Xu S, Entschladen F, Niggemann B, et al.(2001) Migration and metalloproteinases determine the invasive potential of mouse melanoma cells, but not melanin and telomerase. Cancer Lett 162 (Suppl): S49-S55.
65. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, et al.(2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337.
66. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, et al.(2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65: 4320-4333.
67. Grichnik JM, (2006) Genomic instability and tumor stem cells. J Invest Dermatol 126: 1214-1216.
68. Hendrix MJ, Seftor EA, Hess AR, Seftor RE, (2003) Molecular plasticity of human melanoma cells. Oncogene 22: 3070-3075.
69. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, et al.(2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43: 935-946.
70. Wang E, Voiculescu S, Le Poole IC, El-Gamil M, Li X, et al.(2006) Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol 126: 1372-1377.
71. Hendrix MJ, Seftor EA, Hess AR, Seftor RE, (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3: 411-421.
72. Rothhammer T, Bataille F, Spruss T, Eissner G, Bosserhoff AK, (2007) Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene 26: 4158-4170.
73. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, Margaryan NV, Seftor EA, et al.(2006) Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc Natl Acad Sci U S A 103: 3752-3757.
74. Schriek G, Oppitz M, Busch C, Just L, Drews U, (2005) Human SK-Mel 28 melanoma cells resume neural crest cell migration after transplantation into the chick embryo. Melanoma Res 15: 225-234.
75. O'Brien CA, Pollett A, Gallinger S, Dick JE, (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
76. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al.(2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
77. Singh SK, Clarke ID, Hide T, Dirks PB, (2004) Cancer stem cells in nervous system tumors. Oncogene 23: 7267-7273.
78. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al.(2004) Identification of human brain tumour initiating cells. Nature 432: 396-401.
79. Zabierowski SE, Herlyn M, (2008) Melanoma stem cells: the dark seed of melanoma. J Clin Oncol 26: 2890-2894.
80. Torrente Y, Belicchi M, Sampaolesi M, Pisati F, Meregalli M, et al.(2004) Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J Clin Invest 114: 182-195.
81. Anastassiou G, Schilling H, Stang A, Djakovic S, Heiligenhaus A, et al.(2000) Expression of the cell adhesion molecules ICAM-1, VCAM-1 and NCAM in uveal melanoma: a clinicopathological study. Oncology 58: 83-88.
82. Capkovic KL, Stevenson S, Johnson MC, Thelen JJ, Cornelison DD, (2008) Neural cell adhesion molecule (NCAM) marks adult myogenic cells committed to differentiation. Exp Cell Res 314: 1553-1565.
83. Figarella-Branger D, Nedelec J, Pellissier JF, Boucraut J, Bianco N, et al.(1990) Expression of various isoforms of neural cell adhesive molecules and their highly polysialylated counterparts in diseased human muscles. J Neurol Sci 98: 21-36.
84. Buckingham M, Relaix F, (2007) The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions. Annu Rev Cell Dev Biol 23: 645-673.
85. Plummer RS, Shea CR, Nelson M, Powell SK, Freeman DM, et al.(2008) PAX3 expression in primary melanomas and nevi. Mod Pathol 21: 525-530.
86. Dubey RK, Gillespie DG, Mi Z, Jackson EK, (1997) Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: role of A2B receptors. Circulation 96: 2656-2666.
87. Kizaki H, Shimada H, Ohsaka F, Sakurada T, (1988) Adenosine, deoxyadenosine, and deoxyguanosine induce DNA cleavage in mouse thymocytes. J Immunol 141: 1652-1657.
88. Ohana G, Bar-Yehuda S, Barer F, Fishman P, (2001) Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J Cell Physiol 186: 19-23.
89. Boylan MO, Zarbl H, (1991) Transformation effector and suppressor genes. J Cell Biochem 46: 199-205.
90. Klein CA, (2004) Gene expression sigantures, cancer cell evolution and metastatic progression. Cell Cycle 3: 29-31.
91. Zarbl H, Kho CJ, Boylan MO, Van Amsterdam J, Sullivan RC, et al.(1991) Functional in vitro assays for the isolation of cell transformation effector and suppressor genes. Environ Health Perspect 93: 83-89.
92. Rambow F, Malek O, Geffrotin C, Leplat JJ, Bouet S, et al.(2008) Identification of differentially expressed genes in spontaneously regressing melanoma using the MeLiM swine model. Pigment Cell Melanoma Res 21: 147-161.
93. Carreira S, Liu B, Goding CR, (2000) The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes. J Biol Chem 275: 21920-21927.
94. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, et al.(2004) Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6: 565-576.
95. Vance KW, Carreira S, Brosch G, Goding CR, (2005) Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res 65: 2260-2268.
96. Dynek JN, Chan SM, Liu J, Zha J, Fairbrother WJ, et al.(2008) Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res 68: 3124-3132.
97. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, et al.(2002) Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109: 707-718.
98. McGeachie JK, Grounds MD, (1987) Initiation and duration of muscle precursor replication after mild and severe injury to skeletal muscle of mice. An autoradiographic study. Cell Tissue Res 248: 125-130.
99. Montarras D, Morgan J, Collins C, Relaix F, Zaffran S, et al.(2005) Direct isolation of satellite cells for skeletal muscle regeneration. Science 309: 2064-2067.
100. Schwarzkopf M, Coletti D, Sassoon D, Marazzi G, (2006) Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway. Genes Dev 20: 3440-3452.
101. Mouly V, Edom F, Barbet JP, Butler-Browne GS, (1993) Plasticity of human satellite cells. Neuromuscul Disord 3: 371-377.
102. Jackson KA, Snyder DS, Goodell MA, (2004) Skeletal muscle fiber-specific green autofluorescence: potential for stem cell engraftment artifacts. Stem Cells 22: 180-187.